These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

64 related items for PubMed ID: 7537012

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Neoadjuvant hormonal deprivation before radical prostatectomy.
    Schulman CC, Sassine AM.
    Clin Invest Med; 1993 Dec; 16(6):523-31. PubMed ID: 7516836
    [Abstract] [Full Text] [Related]

  • 3. Undetectable prostate specific antigen at 6-12 months: a new marker for early success in hormonally treated patients after prostate brachytherapy.
    Miller N, Smolkin ME, Bissonette E, Theodorescu D.
    Cancer; 2005 Jun 15; 103(12):2499-506. PubMed ID: 15852361
    [Abstract] [Full Text] [Related]

  • 4. [Effect of complete androgen block before radical prostatectomy for cancer of the prostate].
    Gómez Veiga F, Lorenzo Patiño MJ, Díaz Bermúdez J, Duarte Novo J, Alvarez Castelo L, Chantada Abal V, Sánchez Rodríguez J, González Martín M.
    Arch Esp Urol; 1997 May 15; 50(4):355-63. PubMed ID: 9313044
    [Abstract] [Full Text] [Related]

  • 5. Update on Memorial Sloan-Kettering Cancer Center studies of neoadjuvant hormonal therapy for prostate cancer.
    Fair WR, Betancourt JE.
    Mol Urol; 2000 May 15; 4(3):241-8;discussion 249-50. PubMed ID: 11062380
    [Abstract] [Full Text] [Related]

  • 6. Radical prostatectomy and adjuvant endocrine therapy for prostate cancer with or without preoperative androgen deprivation: Five-year results.
    Homma Y, Akaza H, Okada K, Yokoyama M, Moriyama N, Usami M, Hirao Y, Tsushima T, Sakamoto A, Ohashi Y, Aso Y, Prostate Cancer Study Group.
    Int J Urol; 2004 May 15; 11(5):295-303. PubMed ID: 15147545
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Neoadjuvant hormonal therapy in stage C adenocarcinoma of the prostate.
    Andros EA, Danesghari F, Crawford ED.
    Clin Invest Med; 1993 Dec 15; 16(6):510-5. PubMed ID: 7516835
    [Abstract] [Full Text] [Related]

  • 10. Prostate specific antigen doubling time after radical prostatectomy: effect of neoadjuvant androgen deprivation therapy.
    Rabbani F, Perrotti M, Bastar A, Fair WR.
    J Urol; 1999 Mar 15; 161(3):847-52. PubMed ID: 10022699
    [Abstract] [Full Text] [Related]

  • 11. Improved biochemical outcome with adjuvant radiotherapy after radical prostatectomy for prostate cancer with poor pathologic features.
    Vargas C, Kestin LL, Weed DW, Krauss D, Vicini FA, Martinez AA.
    Int J Radiat Oncol Biol Phys; 2005 Mar 01; 61(3):714-24. PubMed ID: 15708249
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. [Clinical study of prostate specific antigen failure after radical prostatectomy for prostate cancer: a single center experience].
    Taue R, Takahashi M, Fukawa T, Koizumi T, Nakanishi R, Yamaguchi K, Yamamoto Y, Nakatsuji H, Kishimoto T, Izaki H, Oka N, Fukumori T, Kanayama HO.
    Hinyokika Kiyo; 2009 Jan 01; 55(1):1-4. PubMed ID: 19227203
    [Abstract] [Full Text] [Related]

  • 14. Correlation of clinical and pathologic factors with rising prostate-specific antigen profiles after radical prostatectomy alone for clinically localized prostate cancer.
    Kupelian P, Katcher J, Levin H, Zippe C, Klein E.
    Urology; 1996 Aug 01; 48(2):249-60. PubMed ID: 8753737
    [Abstract] [Full Text] [Related]

  • 15. Prostate-specific antigen half-life and pretreatment prostate-specific antigen: crucial predictors for prostate-specific antigen trend in delayed-combined androgen blockade therapy.
    Soga N, Onishi T, Arima K, Sugimura Y.
    Int J Urol; 2007 Mar 01; 14(3):192-6; discussion 197. PubMed ID: 17430253
    [Abstract] [Full Text] [Related]

  • 16. Persistent prostate-specific antigen expression after neoadjuvant androgen depletion: an early predictor of relapse or incomplete androgen suppression.
    Ryan CJ, Smith A, Lal P, Satagopan J, Reuter V, Scardino P, Gerald W, Scher HI.
    Urology; 2006 Oct 01; 68(4):834-9. PubMed ID: 17070363
    [Abstract] [Full Text] [Related]

  • 17. [Recurrence following radical surgery for prostatic cancer. Analysis of clinical, biological and anatomo-pathological prognostic factors].
    Feyaerts A, Delrée A, Lorge F, Opsomer RJ, Wese FX, Van Cangh PJ, Draguet AP, Cosyns JP.
    Acta Urol Belg; 1997 Mar 01; 65(1):11-8. PubMed ID: 9245198
    [Abstract] [Full Text] [Related]

  • 18. [Clinical impact of neoadjuvant treatment to radical prostatectomy in locally advanced prostatic cancer].
    Villavicencio H, Laguna P, Ponce de Léon J.
    Actas Urol Esp; 1994 May 01; 18 Suppl():404-8. PubMed ID: 8073926
    [Abstract] [Full Text] [Related]

  • 19. The percent of cores positive for cancer in prostate needle biopsy specimens is strongly predictive of tumor stage and volume at radical prostatectomy.
    Sebo TJ, Bock BJ, Cheville JC, Lohse C, Wollan P, Zincke H.
    J Urol; 2000 Jan 01; 163(1):174-8. PubMed ID: 10604340
    [Abstract] [Full Text] [Related]

  • 20. Phase I-II trial evaluating combined intensity-modulated radiotherapy and in situ gene therapy with or without hormonal therapy in treatment of prostate cancer-interim report on PSA response and biopsy data.
    Teh BS, Ayala G, Aguilar L, Mai WY, Timme TL, Vlachaki MT, Miles B, Kadmon D, Wheeler T, Caillouet J, Davis M, Carpenter LS, Lu HH, Chiu JK, Woo SY, Thompson T, Aguilar-Cordova E, Butler EB.
    Int J Radiat Oncol Biol Phys; 2004 Apr 01; 58(5):1520-9. PubMed ID: 15050332
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.